Company’s 36-month beta value is 2.05.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GLYC is 59.08M, and currently, short sellers hold a 3.91% ratio of that floaft. The average trading volume of GLYC on September 06, 2024 was 3.78M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GLYC) stock’s latest price update
GlycoMimetics Inc (NASDAQ: GLYC) has seen a decline in its stock price by -4.92 in relation to its previous close of 0.16. However, the company has experienced a -9.64% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-07-25 that ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process. “We are committed to acting in the best interests of patients, employees and shareholders. Given our organizat.
GLYC’s Market Performance
GLYC’s stock has fallen by -9.64% in the past week, with a monthly drop of -10.26% and a quarterly drop of -39.88%. The volatility ratio for the week is 6.54% while the volatility levels for the last 30 days are 9.03% for GlycoMimetics Inc The simple moving average for the last 20 days is -11.95% for GLYC stock, with a simple moving average of -89.96% for the last 200 days.
Analysts’ Opinion of GLYC
CapitalOne, on the other hand, stated in their research note that they expect to see GLYC reach a price target of $12. The rating they have provided for GLYC stocks is “Overweight” according to the report published on December 22nd, 2023.
Jefferies gave a rating of “Buy” to GLYC, setting the target price at $4 in the report published on November 12th of the previous year.
GLYC Trading at -32.08% from the 50-Day Moving Average
After a stumble in the market that brought GLYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.57% of loss for the given period.
Volatility was left at 9.03%, however, over the last 30 days, the volatility rate increased by 6.54%, as shares sank -16.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.56% lower at present.
During the last 5 trading sessions, GLYC fell by -9.93%, which changed the moving average for the period of 200-days by -89.24% in comparison to the 20-day moving average, which settled at $0.1762. In addition, GlycoMimetics Inc saw -93.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLYC starting from Invus Public Equities, L.P., who sale 260,873 shares at the price of $0.19 back on Aug 08 ’24. After this action, Invus Public Equities, L.P. now owns 6,317,565 shares of GlycoMimetics Inc, valued at $50,009 using the latest closing price.
Invus Public Equities, L.P., the 10% Owner of GlycoMimetics Inc, sale 61,488 shares at $0.18 during a trade that took place back on Aug 07 ’24, which means that Invus Public Equities, L.P. is holding 6,578,438 shares at $11,197 based on the most recent closing price.
Stock Fundamentals for GLYC
Current profitability levels for the company are sitting at:
- -984455.97 for the present operating margin
- -31.03 for the gross margin
The net margin for GlycoMimetics Inc stands at -3911.41. The total capital return value is set at -490.69. Equity return is now at value -104.49, with -90.71 for asset returns.
Based on GlycoMimetics Inc (GLYC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -79.55. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -16915.63.
Currently, EBITDA for the company is -39.12 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of -1181.33. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.48.
Conclusion
In a nutshell, GlycoMimetics Inc (GLYC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
